Flexion Therapeutics (NASDAQ:FLXN) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.
A number of other equities research analysts have also weighed in on the stock. Janney Montgomery Scott boosted their price objective on shares of Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. Wells Fargo & Co set a $39.00 price objective on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Royal Bank of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Sunday, October 29th. Finally, Northland Securities reissued a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $106.25.
Flexion Therapeutics (NASDAQ:FLXN) opened at $23.41 on Friday. The stock has a market capitalization of $878.83, a price-to-earnings ratio of -6.65 and a beta of 1.14. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a 12-month low of $16.51 and a 12-month high of $32.25.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.09). equities research analysts anticipate that Flexion Therapeutics will post -3.84 EPS for the current year.
In other Flexion Therapeutics news, insider Michael D. Clayman purchased 5,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the acquisition, the insider now owns 35,395 shares in the company, valued at $835,322. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Neil Bodick purchased 2,700 shares of the stock in a transaction on Tuesday, November 21st. The stock was acquired at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the acquisition, the insider now owns 64,605 shares of the company’s stock, valued at approximately $1,582,176.45. The disclosure for this purchase can be found here. 15.98% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. boosted its holdings in Flexion Therapeutics by 53.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 165,222 shares of the specialty pharmaceutical company’s stock valued at $4,138,000 after purchasing an additional 57,672 shares during the last quarter. Berson & Corrado Investment Advisors LLC purchased a new stake in Flexion Therapeutics in the fourth quarter valued at $324,000. Highbridge Capital Management LLC boosted its holdings in Flexion Therapeutics by 408.2% in the third quarter. Highbridge Capital Management LLC now owns 50,823 shares of the specialty pharmaceutical company’s stock valued at $1,229,000 after purchasing an additional 40,823 shares during the last quarter. Gagnon Securities LLC purchased a new stake in Flexion Therapeutics in the third quarter valued at $3,490,000. Finally, Uniplan Investment Counsel Inc. purchased a new stake in Flexion Therapeutics in the third quarter valued at $2,996,000. 72.78% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “BidaskClub Lowers Flexion Therapeutics (FLXN) to Strong Sell” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://transcriptdaily.com/2018/01/20/bidaskclub-lowers-flexion-therapeutics-flxn-to-strong-sell.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.